Skip to main content Accessibility help
×
Home

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response

  • Naomi M. Simon, John J. Worthington, Samantha J. Moshier, Elizabeth H. Marks, Elizabeth A. Hoge, Mina Brandes, Hannah Delong and Mark H. Pollack...

Abstract

Objective: This is the first trial examining duloxetine for generalized social anxiety disorder (GSAD) and the effect of increased dose for those without early remission.

Methods: Individuals (n=39) with GSAD received 6 weeks of open-label duloxetine 60 mg/day; those with a Liebowitz Social Anxiety Disorder Scale (LSAS) score >30 at week 6 were randomized in double-blind fashion to an additional 18 weeks of continued duloxetine 60 mg/day or to duloxetine 120 mg/day.

Results: Duloxetine was associated with a significant LSAS reduction at week 6 (91.3 [17.7] to 69.8 [28.5], paired t [df]=5.2 [38], P<.0001), and randomized participants overall continued to improve at week 24 (74.6 [23.9] to 60.3 [29.7]; paired t [df]=3.3 [27], P=.0026). Though the increased dose strategy was associated with a moderate effect size (Cohen's d=.57), there was no significant difference at week 24 endpoint in LSAS reduction (20.5 [26.0] versus 7.3 [17.2], t [df]=1.6 [26], P=.13) nor remission (33% versus 8%) for duloxetine with dose increased to 120 mg/day compared to duloxetine continued at 60 mg/day. Overall, 44% (17/39) discontinued prior to week 24.

Conclusions: Though with limited power, these data provide preliminary support for the efficacy of duloxetine for GSAD, and suggest continued improvement but limited remission overall at 24 weeks for individuals remaining symptomatic at week 6. These observations warrant further controlled study.

Copyright

Corresponding author

Please direct all correspondence to: Naomi Simon MD, MSc, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Simches Research Building, 2nd Floor, 185 Cambridge St, Boston, MA 02114; Tel: 617-726-7913, Fax: 617-643-3080; e-mail: nsimon@partners.org.

References

Hide All
1.Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593602.
2.Van Ameringen, MA, Lane, RM, Walker, JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158(2): 275281.
3.Stein, MB, Liebowitz, MR, Lydiard, RB, Pitts, CD, Bushnell, W, Gergel, I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998; 280(8): 708713.
4.Stein, MB, al. e. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280288.
5.Stein, MB, Pollack, MH, Bystritsky, A, Kelsey, JE, Mangano, RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280288.
6.Liebowitz, MR, Stein, MB, Tancer, M, Carpenter, D, Oakes, R, Pitts, CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002; 63(1): 6674.
7.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003; 18(2): 5361.
8.Fava, M, Martinez, JM, Greist, J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007; 19(3): 187195.
9.Koponen, H, Allgulander, C, Erickson, J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007; 9(2): 100107.
10.Crippa, JA, Filho, AS, Freitas, MC, Zuardi, AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol. 2007; 27(3): 310.
11.Lin, CC. Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol. 2008; 28(5): 591592; author reply 592–593.
12.Scott, EL, Pollack, MH, Otto, MW, Simon, NM, Worthington, JJ. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis. 1999; 187(12): 755757.
13.First, MS, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axis I DSM-IV Disorders - Patient version (SCID-1/P version 2.0). New York, NY: New York State Psychiatric Institute Biometrics Research Department; 1994.
14.Doyle, AC, Pollack, MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003; 64(Suppl 15): 4045.
15.Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60(Suppl 22): 2934.
16.Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11(Suppl 3): 8995.
17.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2): 321326.
18.Rapaport, MH, Davidson, JR. The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull. 1998; 34(2): 167168.
19.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994; 55(8): 322331.
20.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006; 67(Suppl 12): 2026.
21.Kornstein, SG, Dunner, DL, Meyers, AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry. 2008; 69(9): 13831392.
22.Cymbalta delayed-release capsules. In: Physician's Desk Reference. 63rd ed. Montvale, NJ: Thomson PDR; 2009.

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response

  • Naomi M. Simon, John J. Worthington, Samantha J. Moshier, Elizabeth H. Marks, Elizabeth A. Hoge, Mina Brandes, Hannah Delong and Mark H. Pollack...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed